Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 2270–2272.

https://doi.org/10.1182/blood-2022-163159

Published: 2022

Journal Articles

SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients with Lower-Risk Myelodysplastic Syndrome

Jose F. Falantes, Francisco J. Márquez-Malaver, Estrella Carrillo-Cruz, Rosario M Morales-Camacho, Concepción Prats-Martín, Teresa Caballero, Eduardo Rodriguez Arbolí, Ildefonso Espigado, Jose A. Perez-Simon

Blood (2022) 140 (Supplement 1): 6920–6922.

https://doi.org/10.1182/blood-2022-169372

Published: 2022

Journal Articles

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes

Blood (2021) 138 (Supplement 1): 2606.

https://doi.org/10.1182/blood-2021-146987

Published: 2021

Journal Articles

Measurable Residual Disease (MRD) in Elderly Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-134651

Published: 2020

Journal Articles

Risk-Adapted Intensive Chemotherapy for Primary ACUTE Myeloid Leukemia during the Last 25 YEARS: Increase in Complete Remission RATE, Hematopoietic Cell Transplantation Access and Decrease in Relapse Incidence Have LED to Improved Survival

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-140680

Published: 2020

Journal Articles

A Predictive Model for Early Death after Frontline Hypomethylating Agents in Elderly Unfit Acute Myeloid Leukemia Patients: Results from the Pethema Group

Blood (2019) 134 (Supplement_1): 648.

https://doi.org/10.1182/blood-2019-125053

Published: 2019

Journal Articles

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Blood (2019) 134 (Supplement_1): 3891.

https://doi.org/10.1182/blood-2019-127187

Published: 2019

Journal Articles

Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Blood (2018) 132 (Supplement 1): 433.

https://doi.org/10.1182/blood-2018-99-113299

Published: 2018

Journal Articles

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Blood (2018) 132 (Supplement 1): 1.

https://doi.org/10.1182/blood-2018-99-110805

Published: 2018

Journal Articles

Similar Probabilities of Failure to Reach Transplantation and Transplant Outcomes after HLA-Identical Sibling or Unrelated Donor Transplant in Patients with Acute Myeloid Leukemia: A Single Institution Evaluation of a Donor Selection Algorithm

Eduardo Rodríguez-Arbolí, MD, Francisco J. Márquez-Malaver, RN, Nancy Rodríguez-Torres, MD, Teresa Caballero-Velázquez, MD PhD, Virginia Escamilla Gomez, Cristina Calderón-Cabrera, MD, José F. Falantes, MD, Ildefonso Espigado, MD PhD, José A. Pérez-Simón

Blood (2017) 130 (Supplement 1): 5548.

https://doi.org/10.1182/blood.V130.Suppl_1.5548.5548

Published: 2017

Journal Articles

Multivariable Time-Dependent Analysis Of The Impact Of 5 Azacitidine In Patients With Lower-Risk Myelodysplastic Syndrome and Unfavorable Specific Lower-Risk Score

Blood (2013) 122 (21): 2754.

https://doi.org/10.1182/blood.V122.21.2754.2754

Published: 2013

Journal Articles

The Presence Of 1 / 8 HLA Mismatch Do Not Hamper Survival After Allogeneic Stem Cell Transplantation Using Immunoprophylaxis With Sirolimus-Tacrolimus

Rocío Parody, MD, PhD, Lucía López-Corral, MD, PhD, Oriana Lopez Godino, MD, Irene García Cadenas, Vazquez Lourdes, MD, Rodrigo Martino, MD, PhD, Carmen Martinez, Carlos Solano, Ariadna Perez Martinez, Pere Barba, MD, David Valcarcel, MD, Jose F. Falantes, MD, Francisco J Márquez-Malaver, Dolores Caballero, MD, PhD, Jose Antonio Perez-Simón, MD, PhD

Blood (2013) 122 (21): 4529.

https://doi.org/10.1182/blood.V122.21.4529.4529

Published: 2013

Journal Articles

Azacitidine Alone Or The Combination With Valproic Acid As a Bridge Therapy For Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes Before Transplantation

Cristina Calderón Cabrera, Jose F Falantes, MD, Marina Gómez, Rocío Parody, MD, PhD, Francisco J Márquez Malaver, María L Martino, José González, Isabel Montero, Ildefonso Espigado, Jose Antonio Pérez-Simón

Blood (2013) 122 (21): 2812.

https://doi.org/10.1182/blood.V122.21.2812.2812

Published: 2013

Journal Articles

Multivariate Analysis of the Impact of Pre-Treatment Serum Ferritin Level On Response and Overall Survival in Patients with Myelodysplastic Syndromes Treated with Azacitidine

Regina Garcia Delgado, Dunia de Miguel, Alicia Bailen, José Ramón Gonzalez, Joan Bargay, Jose F Falantes, MD, Rafael Andreu, Fernando Ramos, Mar Tormo, Rafael F Duarte, MD, PhD, Ma José Jiménez Lorenzo, Salut Brunet, Benet Nomdedeu, Antonio Figueredo, Javier Casaño, Llorenç Badiella, Antonio Fernández Jurado, Guillermo Sanz

Blood (2012) 120 (21): 1710.

https://doi.org/10.1182/blood.V120.21.1710.1710

Published: 2012

Journal Articles

Increased Gene Expression Involved in Angiogenesis, Metabolism and Cell Proliferation in Acute Myeloid Leukemia and myelodysplastic Syndromes Correlates with Adverse Clinical and Biological Features

Jose F Falantes, MD, Pablo Trujillo, Cristina Calderón, MD, Jose Gonzalez, MD, Maria Luz Martino, Isabel Montero, MD, Rocio Parody, MD, Ildefonso Espigado, MD, PhD, Jose Antonio Perez-Simón

Blood (2012) 120 (21): 1457.

https://doi.org/10.1182/blood.V120.21.1457.1457

Published: 2012

Journal Articles

Patterns of Infection in Patients with Myeloid Malignancies Receiving 5-Azacytidine: identification of Candidates for Antifungal Prophylaxis

Cristina Calderón, MD, Jose F Falantes, MD, Francisco Márquez-Malaver, MD, Jose González, MD, PhD, Maria Luz Martino, MD, Isabel Montero, MD, Ildefonso Espigado, MD, PhD, Jose Antonio Pérez-Simón, MD, PhD

Blood (2012) 120 (21): 4955.

https://doi.org/10.1182/blood.V120.21.4955.4955

Published: 2012

Journal Articles

Prognostic Factors for Survival and Progression to Acute Myeloid Leukemia in Patients with Lower-Risk Myelodysplastic Syndromes. A New Scoring System

Jose F Falantes, MD, Cristina Calderón, MD, Ildefonso Espigado, MD, PhD, Dora Alonso, MD, Antonio Martín Noya, MD, PhD, Estrella Carrillo, MD, Maria Luz Martino, MD, Isabel Montero, MD, Jose González, MD, PhD, Jose Antonio Pérez-Simón, MD, PhD

Blood (2011) 118 (21): 1730.

https://doi.org/10.1182/blood.V118.21.1730.1730

Published: 2011

Journal Articles

Differential Gene Expression Involved In Angiogenesis, Metabolism, Cell Proliferation and Self-Renewal and Pluripotency In Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Jose F Falantes, MD, Cristina Calderón, MD, Pablo Trujillo, Beatriz Martin-Antonio, Jose González, MD, PhD, Alvaro Urbano, MD, Magdalena Carmona, MD, Ildefonso Espigado, MD, PhD

Blood (2010) 116 (21): 4646.

https://doi.org/10.1182/blood.V116.21.4646.4646

Published: 2010

Journal Articles

Donor's Genetic Variability in NFAT5 and ATBF1, Transcriptional Factors Involved in Cellular Growth and Proliferation, Are Prognostic Factors for Disease Free Survival After Allogeneic Stem Cell Transplantation (Allo-SCT).

Beatriz MArtin Antonio, Isabel álvarez, Francisco Máarquez-Malaver, Pablo Trujillo, Magdalena Carmona, Jose F Falantes, Ildefonso Espigado, A. Urbano-Ispizua

Blood (2009) 114 (22): 2446.

https://doi.org/10.1182/blood.V114.22.2446.2446

Published: 2009

Journal Articles

Azacitidine Is Effective in Patients with Intermediate-2 / High IPSS Risk Myelodysplastic Syndrome Managed in Community Based Practice: Preliminary Data From the Spanish Azacitidine Compassionate Use Registry.

Regina Garcia, MD, José Ramón González, MD, PhD, Alicia Bailen, MD, Jose F Falantes, MD, Joaquin Sanchez, MD, Rafael F Duarte, Juan Besalduch, MD, Andreu Lapiedra, MD

Blood (2009) 114 (22): 4835.

https://doi.org/10.1182/blood.V114.22.4835.4835

Published: 2009

NARROW

Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)

SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients with Lower-Risk Myelodysplastic Syndrome

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes

Measurable Residual Disease (MRD) in Elderly Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

Risk-Adapted Intensive Chemotherapy for Primary ACUTE Myeloid Leukemia during the Last 25 YEARS: Increase in Complete Remission RATE, Hematopoietic Cell Transplantation Access and Decrease in Relapse Incidence Have LED to Improved Survival

A Predictive Model for Early Death after Frontline Hypomethylating Agents in Elderly Unfit Acute Myeloid Leukemia Patients: Results from the Pethema Group

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Similar Probabilities of Failure to Reach Transplantation and Transplant Outcomes after HLA-Identical Sibling or Unrelated Donor Transplant in Patients with Acute Myeloid Leukemia: A Single Institution Evaluation of a Donor Selection Algorithm

Multivariable Time-Dependent Analysis Of The Impact Of 5 Azacitidine In Patients With Lower-Risk Myelodysplastic Syndrome and Unfavorable Specific Lower-Risk Score

The Presence Of 1 / 8 HLA Mismatch Do Not Hamper Survival After Allogeneic Stem Cell Transplantation Using Immunoprophylaxis With Sirolimus-Tacrolimus

Azacitidine Alone Or The Combination With Valproic Acid As a Bridge Therapy For Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes Before Transplantation

Multivariate Analysis of the Impact of Pre-Treatment Serum Ferritin Level On Response and Overall Survival in Patients with Myelodysplastic Syndromes Treated with Azacitidine

Increased Gene Expression Involved in Angiogenesis, Metabolism and Cell Proliferation in Acute Myeloid Leukemia and myelodysplastic Syndromes Correlates with Adverse Clinical and Biological Features

Patterns of Infection in Patients with Myeloid Malignancies Receiving 5-Azacytidine: identification of Candidates for Antifungal Prophylaxis

Prognostic Factors for Survival and Progression to Acute Myeloid Leukemia in Patients with Lower-Risk Myelodysplastic Syndromes. A New Scoring System

Differential Gene Expression Involved In Angiogenesis, Metabolism, Cell Proliferation and Self-Renewal and Pluripotency In Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Donor's Genetic Variability in NFAT5 and ATBF1, Transcriptional Factors Involved in Cellular Growth and Proliferation, Are Prognostic Factors for Disease Free Survival After Allogeneic Stem Cell Transplantation (Allo-SCT).

Azacitidine Is Effective in Patients with Intermediate-2 / High IPSS Risk Myelodysplastic Syndrome Managed in Community Based Practice: Preliminary Data From the Spanish Azacitidine Compassionate Use Registry.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only